| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1068965308 |
| P356 | DOI | 10.2119/MOLMED.2010.00152 |
| P932 | PMC publication ID | 3105153 |
| P698 | PubMed publication ID | 21193899 |
| P5875 | ResearchGate publication ID | 49717038 |
| P50 | author | Charles A. Dinarello | Q834442 |
| Lykke Blaabjerg | Q114369263 | ||
| Thomas Mandrup-Poulsen | Q43220537 | ||
| Joachim Størling | Q45598896 | ||
| P2093 | author name string | Eli C Lewis | |
| Paolo Mascagni | |||
| Sif G Ronn | |||
| P2860 | cites work | Histone deacetylase inhibition modulates indoleamine 2,3-dioxygenase–dependent DC functions and regulates experimental graft-versus-host disease in mice | Q24288997 |
| Generation and characterization of mice transgenic for human IL-18-binding protein isoform a | Q28205411 | ||
| Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes | Q29398493 | ||
| Interleukin-1-receptor antagonist in type 2 diabetes mellitus | Q29619001 | ||
| Pharmacologic induction of fetal hemoglobin: raising the therapeutic bar in sickle cell disease | Q32064107 | ||
| Histone deacetylase inhibitors decrease Toll-like receptor-mediated activation of proinflammatory gene expression by impairing transcription factor recruitment | Q56879954 | ||
| Safety and efficacy of an oral histone deacetylase inhibitor in systemic-onset juvenile idiopathic arthritis | Q61633704 | ||
| Interleukin-1 receptor antagonist prevents low dose streptozotocin induced diabetes in mice | Q72076097 | ||
| Histone hyperacetylation is associated with amelioration of experimental colitis in mice | Q83059529 | ||
| Deficiency of interleukin-18 in mice leads to hyperphagia, obesity and insulin resistance | Q83864443 | ||
| Oral valproic acid for epilepsy--long-term experience in therapy and side effects | Q94681669 | ||
| Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies | Q33369463 | ||
| Histone deacetylase inhibitor ITF2357 is neuroprotective, improves functional recovery, and induces glial apoptosis following experimental traumatic brain injury | Q33613257 | ||
| IL-12-induced IFN-gamma is dependent on caspase-1 processing of the IL-18 precursor | Q33853915 | ||
| The antitumor histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits antiinflammatory properties via suppression of cytokines | Q34015778 | ||
| Histone deacetylase inhibitors: development of suberoylanilide hydroxamic acid (SAHA) for the treatment of cancers. | Q34254451 | ||
| Pharmacological induction of fetal hemoglobin in sickle cell disease and beta-thalassemia | Q34404506 | ||
| The histone deacetylase inhibitor ITF2357 reduces production of pro-inflammatory cytokines in vitro and systemic inflammation in vivo | Q34504770 | ||
| Histone deacetylases and cancer: causes and therapies | Q34570082 | ||
| Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors | Q34687445 | ||
| The histone deacetylase inhibitor ITF2357 selectively targets cells bearing mutated JAK2(V617F). | Q34725589 | ||
| Glucose-induced beta cell production of IL-1beta contributes to glucotoxicity in human pancreatic islets | Q34796756 | ||
| Responses of IL-18- and IL-18 receptor-deficient pancreatic islets with convergence of positive and negative signals for the IL-18 receptor | Q35130769 | ||
| Histone deacetylase inhibitors prevent exocytosis of interleukin-1beta-containing secretory lysosomes: role of microtubules | Q35849001 | ||
| The role of CD40-CD154 interactions in autoimmunity and the benefit of disrupting this pathway | Q35994778 | ||
| The histone deacetylase inhibitor ITF2357 decreases surface CXCR4 and CCR5 expression on CD4(+) T-cells and monocytes and is superior to valproic acid for latent HIV-1 expression in vitro | Q36501927 | ||
| Histone deacetylase inhibitors: molecular and biological activity as a premise to clinical application. | Q36822909 | ||
| Blocking TH17-polarizing cytokines by histone deacetylase inhibitors in vitro and in vivo. | Q37039027 | ||
| Histone deacetylase inhibitor suberoylanilide hydroxamic acid reduces acute graft-versus-host disease and preserves graft-versus-leukemia effect | Q37095317 | ||
| Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4+ T cells | Q37393518 | ||
| Regulatory roles for histone deacetylation in IL-1beta-induced nitric oxide release in pancreatic beta-cells. | Q37568716 | ||
| Blockade of interleukin 1 in type 1 diabetes mellitus | Q37696271 | ||
| Lysine deacetylases are produced in pancreatic beta cells and are differentially regulated by proinflammatory cytokines | Q39650299 | ||
| Inhibition of histone deacetylases prevents cytokine-induced toxicity in beta cells | Q40177074 | ||
| Extracellular signal-regulated kinase is essential for interleukin-1-induced and nuclear factor kappaB-mediated gene expression in insulin-producing INS-1E cells | Q40352211 | ||
| Class I histone deacetylase-selective novel synthetic inhibitors potently inhibit human tumor proliferation | Q40527947 | ||
| Histone deacetylase inhibitors: a new class of immunosuppressors targeting a novel signal pathway essential for CD154 expression | Q44189598 | ||
| Modulation of renal disease in MRL/lpr mice by suberoylanilide hydroxamic acid | Q44904799 | ||
| Valproic acid reduces brain damage induced by transient focal cerebral ischemia in rats: potential roles of histone deacetylase inhibition and heat shock protein induction | Q44930696 | ||
| Glucose- and interleukin-1beta-induced beta-cell apoptosis requires Ca2+ influx and extracellular signal-regulated kinase (ERK) 1/2 activation and is prevented by a sulfonylurea receptor 1/inwardly rectifying K+ channel 6.2 (SUR/Kir6.2) selective po | Q44953905 | ||
| Histone deacetylases: novel targets for prevention of colitis-associated cancer in mice | Q46808312 | ||
| Interleukin-1 beta regulates the expression of a leukocyte type of 12-lipoxygenase in rat islets and RIN m5F cells | Q47637802 | ||
| MCP-1 and MIP-2 expression and production in BB diabetic rat: effect of chronic hypoxia | Q47736823 | ||
| Cutting edge: Negative regulation of dendritic cells through acetylation of the nonhistone protein STAT-3. | Q47884713 | ||
| Reduction of graft-versus-host disease by histone deacetylase inhibitor suberonylanilide hydroxamic acid is associated with modulation of inflammatory cytokine milieu and involves inhibition of STAT1. | Q52932701 | ||
| Differential expression of CC chemokines and the CCR5 receptor in the pancreas is associated with progression to type I diabetes. | Q54045893 | ||
| P433 | issue | 5-6 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 369-377 | |
| P577 | publication date | 2010-12-22 | |
| P1433 | published in | Molecular Medicine | Q6895961 |
| P1476 | title | The oral histone deacetylase inhibitor ITF2357 reduces cytokines and protects islet β cells in vivo and in vitro | |
| P478 | volume | 17 |
| Q37631587 | A Thoroughly Validated Virtual Screening Strategy for Discovery of Novel HDAC3 Inhibitors |
| Q38105550 | Anticipated classes of new medications and molecular targets for pulmonary arterial hypertension |
| Q59812771 | CKD-506, a novel HDAC6-selective inhibitor, improves renal outcomes and survival in a mouse model of systemic lupus erythematosus |
| Q37657613 | Class I and II histone deacetylase inhibition by ITF2357 reduces SLE pathogenesis in vivo |
| Q37628891 | Conditional ablation of HDAC3 in islet beta cells results in glucose intolerance and enhanced susceptibility to STZ-induced diabetes |
| Q88841098 | DNA methylation in systemic lupus erythematosus |
| Q51060521 | Effects of combination therapy with dipeptidyl peptidase-IV and histone deacetylase inhibitors in the non-obese diabetic mouse model of type 1 diabetes. |
| Q55279696 | Epigenetic Programming of Synthesis, Release, and/or Receptor Expression of Common Mediators Participating in the Risk/Resilience for Comorbid Stress-Related Disorders and Coronary Artery Disease. |
| Q55266134 | Epigenetic control of macrophage polarization: implications for targeting tumor-associated macrophages. |
| Q38986705 | Epigenetic drug discovery: breaking through the immune barrier |
| Q39456337 | Epigenetic involvement in etiopathogenesis and implications in treatment of systemic lupus erythematous |
| Q38125919 | Epigenetic regulation of pancreatic islets |
| Q38677989 | Epigenetics and type 1 diabetes: mechanisms and translational applications |
| Q38062497 | Epigenetics in autoimmune diseases with focus on type 1 diabetes |
| Q55004119 | Epigenetics of Subcellular Structure Functioning in the Origin of Risk or Resilience to Comorbidity of Neuropsychiatric and Cardiometabolic Disorders. |
| Q38590582 | Genes affecting β-cell function in type 1 diabetes |
| Q88481159 | Genetic and epigenetic modifications in the pathogenesis of diabetic retinopathy: a molecular link to regulate gene expression |
| Q46382569 | Genistein prevention of hyperglycemia and improvement of glucose tolerance in adult non-obese diabetic mice are associated with alterations of gut microbiome and immune homeostasis |
| Q48162963 | Givinostat reduces adverse cardiac remodeling through regulating fibroblasts activation. |
| Q37838731 | HDAC inhibition in rheumatoid arthritis and juvenile idiopathic arthritis |
| Q41172414 | Histone deacetylase 5 regulates the inflammatory response of macrophages |
| Q38819408 | Histone deacetylase inhibitor givinostat: the small-molecule with promising activity against therapeutically challenging haematological malignancies |
| Q34975260 | Histone deacetylase inhibitor suppresses virus-induced proinflammatory responses and type 1 diabetes |
| Q35016934 | Histone deacetylase inhibitors for treating a spectrum of diseases not related to cancer |
| Q28575131 | Histone deacetylases 1 and 3 but not 2 mediate cytokine-induced beta cell apoptosis in INS-1 cells and dispersed primary islets from rats and are differentially regulated in the islets of type 1 diabetic children |
| Q27000389 | Histone deacetylases as targets for treatment of multiple diseases |
| Q36569602 | ITF2357 transactivates Id3 and regulate TGFβ/BMP7 signaling pathways to attenuate corneal fibrosis |
| Q46155945 | Inhibition of HDAC3 as a strategy for developing novel diabetes therapeutics |
| Q39326566 | Inhibition of histone deacetylase 3 protects beta cells from cytokine-induced apoptosis |
| Q42514281 | Isoform-selective inhibitor of histone deacetylase 3 (HDAC3) limits pancreatic islet infiltration and protects female nonobese diabetic mice from diabetes. |
| Q37956175 | Lysine acetylation in obesity, diabetes and metabolic disease. |
| Q58691841 | MicroRNAs and histone deacetylase inhibition-mediated protection against inflammatory β-cell damage |
| Q36294297 | Molecular targets related to inflammation and insulin resistance and potential interventions |
| Q50067303 | Oral histone deacetylase inhibitor synergises with T cell targeted immunotherapy to preserve beta cell metabolic function and induce stable remission of new-onset autoimmune diabetes in NOD mice |
| Q35564309 | Polyphenols isolated from Broussonetia kazinoki prevent cytokine-induced β-cell damage and the development of type 1 diabetes |
| Q97536645 | Protein acetylation derepresses Serotonin Synthesis to potentiate Pancreatic Beta-Cell Function through HDAC1-PKA-Tph1 signaling |
| Q26774080 | Role of histone deacetylases in pancreas: Implications for pathogenesis and therapy |
| Q35002986 | Specific inhibition of histone deacetylase 8 reduces gene expression and production of proinflammatory cytokines in vitro and in vivo |
| Q34021828 | Synthesis of a novel suppressor of beta-cell apoptosis via diversity-oriented synthesis |
| Q41928977 | Targeting Innate Immunity for Type 1 Diabetes Prevention |
| Q38187862 | Targeting the pancreatic β-cell to treat diabetes |
| Q49717083 | The discovery of novel HDAC3 inhibitors via virtual screening and in vitro bioassay. |
| Q37968302 | The influence of the microbiota on type-1 diabetes: on the threshold of a leap forward in our understanding |
| Q35723616 | The real culprit in systemic lupus erythematosus: abnormal epigenetic regulation |
| Q38537774 | The role of butyrate, a histone deacetylase inhibitor in diabetes mellitus: experimental evidence for therapeutic intervention. |
Search more.